原发性皮肤T淋巴细胞瘤的治疗选择  

Treatment options for primary cutaneous T-cell lymphoma

作　　者：侯秀丽[1] 王平[2] 

机构地区：[1]安徽医科大学杭州临床学院,杭州310009 [2]杭州市第三人民医院

出　　处：《国际皮肤性病学杂志》2014年第5期288-291,共4页International Journal of Dermatology and Venereology

基　　金：浙江省医药卫生科技计划（2014KYB200）

摘　　要：原发性皮肤T细胞淋巴瘤是一组原发于皮肤的淋巴细胞异常增殖性疾病,蕈样肉芽肿是其中最常见的类型.原发性皮肤T细胞淋巴瘤的治疗选择,主要取决于世界卫生组织-欧洲癌症研究和治疗组织-国际皮肤淋巴瘤学会制定的TNMB分期与分类标准,其他需要考虑的因素包括,治疗方法的有效率、起效与持续缓解时间,治疗耐受性与相关毒副作用,治疗实施的难易程度及治疗费用等.原发性皮肤T细胞淋巴瘤早期主张支持治疗和局部治疗为主,晚期则要进行联合化疗,或根据病情辅以免疫调节治疗.一些特异的细胞因子、单克隆抗体和融合毒素也逐步试用于治疗原发性皮肤T细胞淋巴瘤.Primary cutaneous T-cell lymphoma （CTCL） represents a group of diseases characterized by the abnormal proliferation of lymphocytes derived from the skin,with mycosis fungoides （MF） as the most common type.The choice of treatment for CTCL is mainly based on the tumor-node-metastasis-blood （TNMB） classification and staging system for cutaneous lymphomas proposed by the International Society for Cutaneous Lymphomas （ISCL）-World Health Organization-European Organization for Research and Treatment of Cancer （EORTC） in 2007.Other factors to be considered should include the time to onset of action and duration of sustained remission,as well as tolerability,side effects,convenience and cost of treatment.Supportive and local therapies are recommended for early CTCL,while systemic chemotherapy,with or without immunomodulatory therapy,is recommended for advanced CTCL.Some specific cytokines,monoclonal antibodies,and fusion toxins have been tried to treat CTCL.

关 键 词：淋巴瘤 T细胞 皮肤 治疗应用 

分 类 号：R739.5[医药卫生—肿瘤]